Skip to content

Prophylactic Antibiotic Treatment During Vaginal Repair

Antibiotikaprofylakse Ved Vaginalplastik

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00162604
Enrollment
200
Registered
2005-09-13
Start date
2005-05-31
Completion date
Unknown
Last updated
2006-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystocele, Enterocele, Rectocele, Uterine Prolapse

Keywords

Prophylactic antibiotic, Postoperative infections, Uterine prolapse grade I - II, cystocele, rectocele, enterocele, defects of the perineal body

Brief summary

Prolapse of the uterus, bladder and rectum is a common condition in multiparous and/or elderly women. The number of operations for vaginal repair is increasing in Denmark, but there is no consensus or evidence found about the efficiency of prophylactic antibiotics intraoperatively concerning postoperative infections. The objective of this randomized, controlled trial is to investigate the significance of prophylactic antibiotic treatment in vaginal repair operations.

Interventions

DRUGCefuroxime

Sponsors

Hvidovre University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Women ages 18+ with uterine prolapse grade I - II and/or cystocele and/or rectocele and/or enterocele grade I - II and/or defects of the perineal body, in whom there is medical indication for vaginal repair, but no indication for vaginal hysterectomy or transvaginal suspension of the vaginal vault after prior hysterectomy.

Exclusion criteria

* Patients allergic to cefuroxime. * Patients in whom a vaginal hysterectomy or a transvaginal suspension of the vaginal vault or other major surgery is planned, where prophylactic antibiotic treatment is standard. * Patients suffering from physical or mental disorders that will not allow them to give informed consent. * Pregnant and nursing women.

Design outcomes

Primary

MeasureTime frame
primary endpoint: no infections (urinary tract infections, pneumonia,wound infections, infected haematomas, etc.) within 30 days postoperatively

Countries

Denmark

Contacts

Primary ContactMarianne Ottesen, M.D
marianne.8sen@dadlnet.dk0045 36323632

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026